← Back to all trials
Terminated
NCT07036718
NIS PDC the Efficacy and Safety of Iptacopan in Adults in Routine Clinical Practice
Conditions: Paroxysmal Nocturnal Hemoglobinuria
Sex: All
Ages: 18 Years – N/A
Healthy volunteers: No
Enrollment: 6
Sponsor: Novartis Pharmaceuticals
Location: Novartis Investigative Site Syktyvkar Komi
Summary
This is a prospective, non-interventional, multicenter study to evaluate the efficacy and safety of iptacopan in patients with PNH in real-world settings in Russia.
Eligibility Criteria
Inclusion Criteria:
1. Age ≥18 years at the start of iptacopan therapy.
2. The patient is undergoing treatment with iptacopan.
3. The treating physician decided to prescribe iptacopan based on the Summary of Product Characteristics during routine clinical practice, regardless of study participation.
4. Provision of written informed consent.
Exclusion Criteria:
1\. Any situations where iptacopan is contraindicated in accordance with the Summary of Product Characteristics.
Source: ClinicalTrials.gov (NCT07036718). StuddyBuddy aggregates publicly available trial information.
